FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results
February 18 2020 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and
full year 2019 financial results after market close on Monday,
March 2, 2020. FibroGen will also conduct a conference call on that
day at 5:00 p.m. (2:00 p.m. PT) with the investment community to
further detail the company's corporate and financial performance.
Conference Call and Audio Webcast Interested
parties may access a live audio webcast of the conference call via
the FibroGen website at
https://fibrogen.gcs-web.com/events-and-presentations/events. It is
recommended that listeners access the website 15 minutes prior to
the start of the call to download and install any necessary audio
software.
Dial-In InformationLive (U.S./Canada): (877)
658-9081Live (International): (602) 563-8732Confirmation number:
8058848
A replay of the webcast will be available shortly after the call
for a period of two weeks. To access the replay, please dial (800)
585-8367 (domestic) or (404) 537-3406 (international), and use
passcode 8058848#.
About FibroGenFibroGen, Inc., headquartered in
San Francisco, California, with subsidiary offices in Beijing and
Shanghai, People’s Republic of China, is a leading
biopharmaceutical company discovering and developing a pipeline of
first-in-class therapeutics. The company applies its pioneering
expertise in hypoxia-inducible factor (HIF) and connective tissue
growth factor (CTGF) biology, and clinical development to advance
innovative medicines for the treatment of anemia, fibrotic disease,
and cancer. Roxadustat, the company’s most advanced product, is an
oral small molecule inhibitor of HIF prolyl hydroxylase (HIF-PH)
activity, completing worldwide Phase 3 clinical development for the
treatment of anemia in chronic kidney disease (CKD), is approved by
the National Medical Products Administration (NMPA) in China for
CKD patients on dialysis and not on dialysis, and by the Ministry
of Health, Labour and Welfare (MHLW) in Japan for CKD patients on
dialysis. The NDA for roxadustat for treatment of CKD anemia was
accepted for filing by the U.S. FDA in February 2020. Roxadustat is
in Phase 3 clinical development in the U.S. and Europe and in Phase
2/3 development in China for anemia associated with myelodysplastic
syndromes (MDS), and in a Phase 2 U.S. trial for treatment of
chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human
monoclonal antibody, is in Phase 3 clinical development for the
treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic
cancer, and is currently in a Phase 2 trial for Duchenne muscular
dystrophy (DMD). FibroGen is also developing a biosynthetic cornea
in China. For more information, please visit www.fibrogen.com.
Contact: FibroGen, Inc.
Media Inquiries: Sara Iacovino 1.703.474.4452
sara.iacovino@gcihealth.com
Investors: Michael Tung, M.D. Investor Relations 1.415.978.1433
ir@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024